Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 33.17 | 28.81 | 27.77 | 24.37 | 23.31 | 27.89 | 48.68 | 28.76 | 29.00 | — | 24.82 | 27.42 | 21.90 | 24.99 | 29.28 | 22.92 | 20.16 | 22.51 | 22.04 | 18.30 | 13.83 |
| — | +3.3% | -43.0% | -15.3% | -19.6% | — | +96.1% | +4.9% | +32.4% | — | -15.2% | +19.6% | +8.6% | +11.0% | +32.8% | +25.2% | +45.8% | -88.4% | +2.2% | -28.8% | -48.6% | |
| P/S Ratio | 10.68 | 9.52 | 9.58 | 8.99 | 8.20 | 9.72 | 11.35 | 9.01 | 10.95 | 11.43 | 10.15 | 10.54 | 9.12 | 9.19 | 8.63 | 8.16 | 8.05 | 8.30 | 8.02 | 6.81 | 5.94 |
| — | -2.0% | -15.6% | -0.1% | -25.1% | -15.0% | +11.8% | -14.6% | +20.0% | +24.4% | +17.6% | +29.2% | +13.4% | +10.7% | +7.6% | +19.9% | +35.6% | +13.1% | -1.7% | -28.7% | -49.2% | |
| P/B Ratio | 7.02 | 6.27 | 5.91 | 6.22 | 5.83 | 6.71 | 7.63 | 6.39 | 7.77 | 8.19 | 5.88 | 6.04 | 5.49 | 5.92 | 5.68 | 5.40 | 5.77 | 6.11 | 6.17 | 5.59 | 4.94 |
| — | -6.5% | -22.5% | -2.7% | -25.0% | -18.0% | +29.6% | +5.9% | +41.5% | +38.2% | +3.6% | +11.8% | -4.8% | -3.0% | -7.9% | -3.3% | +16.7% | +6.7% | -1.5% | -21.9% | -44.1% | |
| P/FCF | 40.38 | 31.34 | 22.10 | 83.27 | 22.13 | 31.07 | 40.42 | 53.30 | 23.31 | — | 25.78 | 150.36 | 18.45 | 21.31 | 23.90 | 17.99 | 20.84 | 16.77 | 18.85 | 15.12 | 13.46 |
| — | +0.9% | -45.3% | +56.2% | -5.0% | — | +56.7% | -64.5% | +26.3% | — | +7.9% | +736.0% | -11.5% | +27.1% | +26.8% | +19.0% | +54.8% | — | +13.9% | -56.8% | -45.1% | |
| EV / EBITDA | 25.72 | 22.06 | 23.23 | 21.22 | 19.71 | 23.24 | 45.24 | 23.80 | 25.19 | — | 21.10 | 23.05 | 18.57 | 19.26 | 22.47 | 15.29 | 14.35 | 14.22 | 14.06 | 13.88 | 9.60 |
| — | -5.1% | -48.7% | -10.8% | -21.8% | — | +114.4% | +3.2% | +35.6% | — | -6.1% | +50.8% | +29.4% | +35.4% | +59.8% | +10.2% | +49.5% | — | +1.4% | -24.7% | -60.0% | |
| EV / EBIT | 26.84 | 22.06 | 22.14 | 21.53 | 18.77 | 21.73 | 41.85 | 22.40 | 23.92 | — | 19.52 | 20.85 | 16.86 | 17.54 | 20.35 | 15.06 | 14.03 | 15.65 | 15.62 | 14.28 | 9.50 |
| — | +1.5% | -47.1% | -3.9% | -21.5% | — | +114.4% | +7.4% | +41.9% | — | -4.1% | +38.5% | +20.2% | +12.0% | +30.3% | +5.5% | +47.7% | — | +2.7% | -9.5% | -57.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.0% | 85.3% | 86.8% | 85.6% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% | 85.9% | 87.3% | 85.4% | 87.2% | 87.6% | 88.8% | 87.7% | 87.6% | 88.1% | 88.3% | 88.1% | 88.1% |
| — | -1.1% | -0.1% | +0.1% | +0.8% | +0.4% | -0.4% | +0.1% | -1.5% | -1.9% | -1.7% | -2.6% | -0.5% | -0.5% | +0.5% | -0.4% | -0.5% | +0.9% | -0.6% | +0.6% | +0.2% | |
| Operating Margin | 39.4% | 37.4% | 38.1% | 40.3% | 38.6% | 38.8% | 22.7% | 35.2% | 40.3% | -132.9% | 42.4% | 39.3% | 41.8% | 41.2% | 32.8% | 44.9% | 48.3% | 50.4% | 49.6% | 42.3% | 53.1% |
| — | -3.6% | +67.5% | +14.4% | -4.3% | +129.2% | -46.4% | -10.3% | -3.7% | -422.7% | +29.3% | -12.5% | -13.4% | -18.3% | -33.9% | +6.0% | -9.2% | +2483.6% | -3.6% | -7.6% | +21.6% | |
| Net Margin | 32.7% | 33.0% | 34.5% | 36.9% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% | -135.8% | 40.9% | 38.5% | 41.7% | 36.7% | 29.5% | 35.6% | 39.9% | 36.9% | 36.3% | 37.2% | 42.9% |
| — | -5.3% | +48.0% | +17.7% | -6.7% | +125.6% | -43.0% | -18.5% | -9.5% | -469.8% | +38.9% | +8.2% | +4.6% | -0.5% | -18.9% | -4.3% | -7.2% | +889.0% | -4.1% | +0.1% | -1.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.5% | 5.6% | 5.4% | 6.6% | 6.3% | 6.1% | 3.9% | 5.7% | 6.9% | -21.6% | 6.1% | 5.7% | 6.5% | 6.1% | 4.9% | 6.1% | 7.5% | 7.1% | 7.3% | 7.8% | 9.1% |
| — | -9.5% | +38.1% | +16.2% | -8.7% | +128.4% | -35.5% | +0.3% | +6.2% | -452.2% | +23.3% | -6.5% | -13.2% | -13.7% | -31.9% | -22.5% | -18.1% | +863.7% | -1.9% | +9.2% | +6.7% | |
| ROA | 16.2% | 4.1% | 3.9% | 4.7% | 4.4% | 4.4% | 2.8% | 4.1% | 4.9% | -16.3% | 4.7% | 4.4% | 4.9% | 4.7% | 3.8% | 4.7% | 5.8% | 5.4% | 5.5% | 5.9% | 6.9% |
| — | -7.3% | +37.7% | +14.5% | -10.2% | +127.0% | -39.6% | -6.4% | +0.3% | -450.3% | +25.1% | -7.2% | -14.6% | -14.3% | -31.5% | -20.5% | -16.0% | +887.7% | +0.6% | +12.8% | +10.6% | |
| ROIC | 23.0% | 5.9% | 5.1% | 6.2% | 6.4% | 6.3% | 3.5% | 6.0% | 7.2% | -24.8% | 9.4% | 10.5% | 12.7% | 12.8% | 11.4% | 17.2% | 19.3% | 20.1% | 18.5% | 15.7% | 19.4% |
| — | -7.7% | +46.7% | +2.8% | -11.7% | +125.6% | -63.0% | -42.7% | -43.4% | -293.8% | -17.4% | -39.3% | -34.0% | -36.3% | -38.2% | +10.1% | -0.5% | +2786.9% | -0.1% | -2.6% | +25.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.10 | 0.10 | 0.21 | 0.11 | 0.09 | 0.10 | 0.11 | 0.11 | 0.06 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.08 | 0.10 | 0.09 |
| — | +9.8% | +2.6% | +95.1% | -2.8% | +40.8% | +157.0% | +131.9% | +141.6% | +27.3% | -28.9% | -28.9% | -28.7% | -30.1% | -31.6% | -32.5% | -31.2% | -26.9% | -20.1% | -10.7% | +36.9% | |
| Debt / EBITDA | 0.78 | 1.42 | 1.66 | 2.87 | 1.48 | 1.27 | 2.43 | 1.63 | 1.46 | — | 0.60 | 0.77 | 0.69 | 0.72 | 0.97 | 0.84 | 0.71 | 0.74 | 0.81 | 1.06 | 0.81 |
| — | +11.9% | -31.5% | +75.8% | +1.6% | — | +302.0% | +111.4% | +111.2% | — | -37.3% | -8.1% | -2.7% | -3.0% | +19.1% | -20.9% | -12.2% | — | -17.4% | -11.7% | +3.2% | |
| Current Ratio | 2.90 | 3.19 | 3.02 | 2.90 | 2.36 | 2.52 | 2.65 | 2.69 | 2.47 | 2.52 | 3.50 | 3.99 | 4.08 | 4.14 | 4.28 | 4.83 | 4.70 | 4.50 | 4.75 | 4.46 | 4.62 |
| — | +26.4% | +14.3% | +7.8% | -4.3% | -0.0% | -24.4% | -32.5% | -39.6% | -39.1% | -18.3% | -17.4% | -13.2% | -8.0% | -9.8% | +8.1% | +1.7% | -2.3% | +8.2% | +3.0% | +24.3% | |
| Quick Ratio | 2.46 | 2.74 | 2.57 | 2.46 | 2.00 | 2.16 | 2.29 | 2.35 | 2.20 | 2.26 | 3.29 | 3.78 | 3.89 | 3.96 | 4.11 | 4.66 | 4.55 | 4.36 | 4.60 | 4.30 | 4.45 |
| — | +26.9% | +12.3% | +4.7% | -9.0% | -4.7% | -30.4% | -37.7% | -43.6% | -42.8% | -20.0% | -18.9% | -14.5% | -9.1% | -10.6% | +8.4% | +2.3% | -1.7% | +8.5% | +2.8% | +23.6% | |
| Interest Coverage | 350.11 | — | — | 404.33 | 394.58 | 347.76 | 244.47 | 406.89 | 164.21 | -341.55 | 123.99 | 109.26 | 109.18 | 104.71 | 79.20 | 93.83 | 86.87 | 71.16 | 65.08 | 58.68 | 71.98 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VRTX stock.
Vertex Pharmaceuticals Incorporated's current P/E is 33.2x. The average P/E over the last 4 quarters is 26.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Vertex Pharmaceuticals Incorporated's current operating margin is 39.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vertex Pharmaceuticals Incorporated's business trajectory between earnings reports.